EPISODE · May 17, 2026 · 3 MIN
CAR-T Therapy Autoimmune Alert: 2026 Market Risk
from Signal Daily News · host Signal Daily News
[object Object]
What this episode covers
Early CAR-T trials show durable remission in MS, lupus, and stiff person syndrome. Could this disrupt the $150B immunosuppressant market? The real shift is in the business model.
NOW PLAYING
CAR-T Therapy Autoimmune Alert: 2026 Market Risk
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m